BezjakA, TuD, SeymourL, et al.Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2006; 24:3831-7.
2.
RobertC, SoriaJC, SpatzA, et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005; 6:491-500.
3.
Perez-SolerR.Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology, 2003; 17Suppl 12:23-8.
